EMA suspends fenspiride medicines due to heart rhythm risks
The EMA has announced an EU-wide suspension of fenspiride medicines due to a potential risk of heart rhythm problems.
Read More
Tag: heart rhythm problems
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
